![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinopharm’s COVID-19 Vaccine Generated Antibodies in Trials
Sinopharm’s COVID-19 Vaccine Generated Antibodies in Trials
Sinopharm’s COVID-19 vaccine candidate has triggered antibody responses in early-stage trials.
Almost all participants in the phase 1 and 2 trials who received the vaccine had an antibody response. The phase 1 trial tested three different doses in 96 participants, while the phase 2 study tested a medium dose in 224 participants.
Sinopharm’s COVID-19 vaccine is currently in phase 3 testing in the United Arab Emirates.
Upcoming Events
-
21Oct